pre-seed
Stage
1
Investors
About
Nova Anchora is developing NvA-021, a corrective topical biologic therapy gel for Dystrophic Epidermolysis Bullosa (DEB), a rare genetic skin disease. The gel delivers a genetically corrected version of collagen VII to improve wound healing in patients.
Explore Nova Anchora's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.